Table 1. Characteristics of DRTB patients at treatment start stratified by HIV status.
| Characteristics | HIV negative | HIV positive | p-value | Overall |
|---|---|---|---|---|
| N = 951 | N = 418 | N = 1,369 | ||
| N(%) | N(%) | N(%) | ||
| Project location | <0.001 | |||
| Abkhazia | 17 (1.8) | 13 (3.1) | 30 (2.2) | |
| Armenia | 528 (55.5) | 40 (9.6) | 568 (41.5) | |
| Colombia | 53 (5.6) | 1 (0.2 | 54 (3.9) | |
| Kenya | 44 (4.6) | 27 (6.5) | 71 (5.2) | |
| Kyrgyzstan | 93 (9.8) | 4 (1.0) | 97 (7.1) | |
| Swaziland | 80 (8.4) | 333 (79.7) | 413 (30.2) | |
| Uzbekistan | 136 (14.3) | 0 (0.0) | 136 (9.9) | |
| Gender | <0.001 | |||
| Male | 683 (71.8) | 195 (46.6) | 878 (64.1) | |
| Female | 268 (28.2) | 223 (54.4) | 491 (35.9) | |
| Age (years) | 0.001 | |||
| Median [IQR] | 36 [26–48] | 33 [27–40] | 34 [27–46] | |
| < 35 | 445 (47.0) | 236 (57.3) | 681 (50.1) | |
| ≥ 35 | 501 (53.0) | 176 (42.7) | 677 (49.9) | |
| Missing | 5 | 6 | 11 | |
| Ex-prisoner | 0.084 | |||
| No | 834 (87.7) | 380 (90.9) | 1,214 (88.7) | |
| Yes | 117 (12.3) | 38 (9.1) | 155 (11.3) | |
| Contact of a MDR-TB case | <0.001 | |||
| No | 835 (87.9) | 406 (97.1) | 1,241 (90.7) | |
| Yes | 115 (12.1) | 12 (2.9) | 127 (9.3) | |
| Missing | 1 | 0 | 1 | |
| History of previous anti-TB treatment | <0.001 | |||
| New case | 417 (45.1) | 106 (25.9) | 523 (39.2) | |
| Previously treated with FLD | 357 (38.6) | 265 (64.6) | 622 (46.6) | |
| Previously treated with SLD | 130 (14.0) | 29 (7.1) | 159 (11.9) | |
| Transferred in | 21 (2.3) | 10 (2.4) | 31 (2.3) | |
| Missing | 26 | 8 | 34 | |
| BMI | 0.201 | |||
| < 18.5 | 205 (32.9) | 142 (36.8) | 347 (34.4) | |
| ≥ 18.5 | 419 (67.1) | 244 (63.2) | 663 (65.6) | |
| Missing | 327 | 32 | 359 | |
| Cavities on CXR | <0.001 | |||
| No | 300 (31.5) | 312 (74.6) | 612 (44.7) | |
| Yes | 651 (68.5) | 106 (25.4) | 757 (55.3) | |
| Diabetes | - | |||
| No | 746 (91.4) | 418 (100) | 1,164 (94.3) | |
| Yes | 70 (8.6) | 0 (0.0) | 70 (5.7) | |
| Missing | 135 | 0 | 135 | |
| Smear result | 0.014 | |||
| Negative | 272 (32.5) | 116 (32.0) | 388 (32.4) | |
| 1+ | 183 (21.9) | 94 (26.0) | 277 (23.1) | |
| 2+ | 158 (18.9) | 41 (11.3) | 199 (16.6) | |
| 3+ | 223 (26.6) | 111 (30.7) | 334 (27.9) | |
| Scanty | 1 (0.1) | 0 (0.0) | 1 (0.1) | |
| Missing | 114 | 56 | 170 | |
| DST profile† | ||||
| PDR | <0.001 | |||
| H(S) | 211 (73.3) | 27 (33.3) | 238 (64.5) | |
| HE(S) | 44 (15.3) | 36 (44.5) | 80 (21.7) | |
| R(E)(S) | 33 (11.5) | 18 (22.2) | 51 (13.8) | |
| Other | 30 | 27 | 57 | |
| MDR/XDR | 0.459 | |||
| H and R resistant only | 211 (59.9) | 24 (63.2) | 235 (60.3) | |
| Pre-XDR (1 injectable) | 33 (9.4) | 6 (15.8) | 39 (10.0) | |
| Pre-XDR (2 injectables) | 36 (10.2) | 1 (2.6) | 37 (9.5) | |
| Pre-XDR Fluoroquinolones | 42 (11.9) | 4 (10.5) | 46 (11.8) | |
| XDR | 30 (8.5) | 3 (7.9) | 33 (8.5) | |
| SLD line resistance missing | 246 | 173 | 419 |
† 134 DRTB patients could not be classified as PDR or MDR/XDR